Prospect Venture Partners

Total investments

90

Average round size

29M

Portfolio companies

48

Rounds per year

3.46

Lead investments

12

Follow on index

0.47

Exits

24

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

The main office of represented VC is situated in the Palo Alto. The company was established in North America in United States.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Prospect Venture Partners, startups are often financed by Venrock, Three Arch Partners, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Three Arch Partners, ARCH Venture Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Alta Partners, Versant Ventures.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Kythera Biopharmaceuticals, NGM Biopharmaceuticals, Topica Pharmaceuticals. The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Biopharma, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The fund is generally included in 2-6 deals every year. The high activity for fund was in 2004. Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2019. The average startup value when the investment from Prospect Venture Partners is 10-50 millions dollars. This Prospect Venture Partners works on 8 percentage points less the average amount of lead investments comparing to the other organizations.

This organization was formed by Alex Barkas. Besides them, we counted 1 critical employee of this fund in our database.

Show more

Investments analytics

Analytics

Total investments
90
Lead investments
12
Exits
24
Rounds per year
3.46
Follow on index
0.47
Investments by industry
  • Biotechnology (64)
  • Health Care (60)
  • Pharmaceutical (34)
  • Medical (29)
  • Medical Device (27)
  • Show 22 more
Investments by region
  • United States (89)
  • Belgium (1)
Peak activity year
2004
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
3

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
19
Avg. valuation at time of investment
158M
Group Appearance index
0.94
Avg. company exit year
11
Avg. multiplicator
2.29
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Allux Medical 30 Sep 2004 Biotechnology, Health Care, Medical Device Early Stage Venture 800K United States, California
Huangjinguanjia 04 May 2018 Financial Services, FinTech, Finance Early Stage Venture 0 China, Beijing, Dongcheng District
Idun Pharmaceuticals 15 Jun 2004 Biotechnology, Therapeutics, Biopharma Early Stage Venture 27M United States, California, San Diego

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.